This study compares 3D dose distributions obtained with voxel S values (VSVs) for soft tissue, calculated by several methods at their current state-of-the-art, varying the degree of image blurring. The methods were: 1) convolution of Dose Point Kernel (DPK) for water, using a scaling factor method; 2) an analytical model (AM), tting the deposited energy as a function of the source-target distance; 3) a rescaling method (RSM) based on a set of high-resolution VSVs for each isotope; 4) local energy deposition (LED For unblurred spheroidal clusters, ∆D 95% , ∆D 50% and ∆D max were mostly within some percents, slightly higher for 177 Lu with DPK (8%) and RSM (12%) and considerably higher for LED (∆D 95% up to 59%). Increasing the blurring, differences decreased and also LED yielded very similar results, but D 95% and D 50% underestimations between 30-60% and 15-50%, respectively (with respect to 3D-dosimetry with unblurred distributions), were evidenced. Also for clinical images (affected by blurring as well), cDVHs differences for most methods were within few percents, except for slightly higher differences with LED, and almost systematic for dose pro les with DPK (−1.2%), AM (−3.0%) and RSM (4.5%), whereas showed an oscillating trend with LED.
For unblurred spheroidal clusters, ∆D 95% , ∆D 50% and ∆D max were mostly within some percents, slightly higher for 177 Lu with DPK (8%) and RSM (12%) and considerably higher for LED (∆D 95% up to 59%). Increasing the blurring, differences decreased and also LED yielded very similar results, but D 95% and D 50% underestimations between 30-60% and 15-50%, respectively (with respect to 3D-dosimetry with unblurred distributions), were evidenced. Also for clinical images (affected by blurring as well), cDVHs differences for most methods were within few percents, except for slightly higher differences with LED, and almost systematic for dose pro les with DPK (−1.2%), AM (−3.0%) and RSM (4.5%), whereas showed an oscillating trend with LED.
The major concern for 3D-dosimetry on clinical SPECT images is more strongly represented by image blurring than by differences among the VSVs calculation methods. For volume sizes about 2-fold the spatial resolution, D 95% and D 50% underestimations up to about 60 and 50% could result, so the usefulness of 3D-dosimetry is highly questionable for small tumors, unless adequate corrections for partial volume effects are adopted.
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Introduction
The continuous improvement and diffusion of hybrid SPECT-CT and PET-CT scanners has encouraged the calculation of (3D) dose distributions in targeted radionuclide therapy (TRT), using non-uniform activity distributions.
In the historical background of Monte Carlo (MC)-based internal dosimetry, the convolution of dose point-kernels (DPKs) with the 3D activity distribution was widely recommended when dealing with uniform media, as computationally more ef cient than real-time MC calculations (Giap et al 1995 . DPKs for electrons and photons were calculated with MC codes and tabulated, introducing also analytical models to approximate dose-kernels and simplify the convolution algorithms (Leichner et al 1989 , Prestwich et al 1989 , Cross 1997 . Subsequently, several groups updated the DPKs tabulations, comparing the results obtained with more recent MC codes (Janicki and Seuntjens 2004 , Uusijärvi et al 2009 , Botta et al 2011 , Papadimitroulas et al 2012 .
The voxel S values (VSVs) approach, introduced by the MIRD Committee (Bolch et al 1999) , became more popular than DPKs, due to its recognized simplicity and reliability (Gardin et al 2003 , Sarfaraz et al 2004 , Dieudonné et al 2011 , Ferrari et al 2012 . In this approach, the average absorbed dose to the target voxel (t) can be calculated as:
where Ã S is the time-integrated activity in the source voxel (s) and S t ← s is de ned as:
M Pacilio et al Phys. Med. Biol. 60 (2015 ) 1945 where ∆ i is the mean energy emitted as radiation i per decay, φ i is the absorbed fraction in t of the radiation i emitted in s and m t is the mass of the target voxel. VSVs must be calculated for each clinical setting, due to differences in reconstruction matrices, zoom factors (which involve changes in voxel size and/or shape) and absorbing medium. The differences among MC codes in the calculation of VSVs were studied afterwards, investigating also their impact on dosimetric calculations (Pacilio et al 2009) . Recently, a freely available database of VSVs, calculated by direct MC simulations, was presented for seven radionuclides and thirteen voxel sizes in soft or bone tissues (Lanconelli et al 2012) . To date, several strategies to calculate VSVs have been developed, exploiting direct MC computations (Strigari et al 2006 , Pacilio et al 2009 , Lanconelli et al 2012 , Amato et al 2013a , convolution (Erdi et al 1998) or numerical integration of DPKs (Franquiz et al 2003) . A method to calculate VSVs for a generic voxel size, by means of nuclide-speci c ne-resolution VSVs (obtained with MC simulations) and a re-sampling procedure, was introduced by Dieudonné et al (2010) . An analytical model for the calculation of VSVs for a generic electron and photon emission spectrum in cubic voxel sizes was proposed by Amato et al (2012) . A rescaling method for obtaining VSVs for arbitrary voxel sizes based on ts, interpolations and re-samplings starting from nuclide-speci c high-resolution VSVs was proposed by Fernández et al (2013) .
Besides convolution techniques, direct MC simulation is considered the gold standard, since it accounts for inhomogeneity of absorbing media (Furhang et al 1997) . Several studies pointed out the feasibility of real-time MC dosimetry (Sgouros and Kolbert 2002 , Chiavassa et al 2006 , Prideaux et al 2007 , Hobbs et al 2009 , Botta et al 2013 , the most remarkable of which presented the 3D-RD software (Prideaux et al 2007 , Hobbs et al 2009 . Despite the promising potentialities, MC-based treatment planning systems for TRT are not yet commercially available and the computational skills to implement them are not always present in clinical departments. So nowadays, the approach of convolution calculations by VSVs continues to play a role, at least for anatomic regions characterized by nearlyuniform density tissue (Dieudonné et al 2013) .
The aim of this work is to compare the VSVs calculated by different currently available methods, studying the impact of the differences on 3D dose distributions. The methods employed have been previously validated by their proponents and were tested here at their state-of-the-art. So dose differences may derive from either methodology, or possible slight mismatches among input data for calculations (energy spectra, medium density and composition). Three methods are considered: 1. MC volume integration of DPKs (Cornejo Diaz et al 2006 , Casacó et al 2008 ; 2. the analytical model presented by Amato et al (2012) ; 3. the rescaling method proposed by Fernández et al (2013) . The local energy deposition (LED) hypothesis was also tested, assuming that all kinetic energy released from the emitted electrons is locally absorbed within the source voxel (Ljungberg and Sjögreen-Gleisner 2011, Chiesa et al 2012) . The LED assumption may be useful to overcome the need of VSVs calculation and simplify dosimetric calculations for pure beta emitters, while the gamma emission, when present, must be accounted for by convolution. The VSVs obtained with direct MC simulations by Lanconelli et al (2012) were used as a reference. 3D dose distributions were compared in terms of cumulative Dose Volume Histograms (cDVHs) and dose pro les. Voxel-based models consisting of homogeneous spheroidal clusters of soft tissue were considered rst, with uniform activity distribution of several radionuclides: 177 Lu results are included in the supplementary data, (stacks.iop.org/PMB/60/051945) for reasons of space). The in uence of typical spatial resolutions of real SPECT systems on dosimetric differences was also studied, blurring the activity distribution by Gaussian point spread functions (PSF) with various widths. Dosimetric differences were analysed also in clinical settings (non-uniform activity distributions) performing 3D dosimetry for patients treated with 90 Y derivatives.
Materials and methods
2.1. Calculation of VSVs 2.1.1. Convolution of DPKs. This method (Cornejo Diaz et al 2006) employs DPKs in water from the literature: the discrete DPKs published by Cross et al (Cross 1997 , Cross et al 1992 for beta radiation, and the analytical functions of DPKs given by Furhang et al (1996) for gamma radiation. The discrete DPKs for beta radiation is tted with empirical analytical functions, obtaining a maximum deviation with respect to the published values within 1.0% (Cornejo Diaz et al 2006) . MC volume integration for each pair of source-target voxels is performed, obtaining the corresponding VSV, according to Franquiz et al (2003) . Brie y, a given number (~10 6 ) of pairs of random points (one inside the source voxel, one in the target voxel) is simulated, and the corresponding absorbed dose rate is calculated for each distance between the two points. The S t ← s for the pair of voxels is then obtained as the mean value of the absorbed doses from all couples of points. A correction is applied to the DPKs in waterbased on the scaling factor method proposed by Cross et al (1992) -to calculate the S factors for the beta radiation in media other than water. The dose rate in the medium of interest (at a given distance r) is calculated from the dose rate in water as:
where η W denotes the scaling factor, or relative attenuation of beta radiation for the considered medium compared to water, D(r) and D W (r) are the absorbed dose in the medium and water at the distance r and ρ, ρ W are the densities of the medium and water, respectively. The methodology is implemented with a software developed in-house (Konvox, Borland Delphi 3 environment).
2.1.2. Analytical calculation method. The analytical method for calculating VSVs, referred to a generic beta-gamma emitting radionuclide, was previously described (Amato et al 2012 , Amato et al 2013b . It employs MC simulations with GEANT4 (Agostinelli et al 2003) of monoenergetic electrons and photons in voxelized regions of soft tissue with density 1.04 g cm −3 and composition from ICRP Publication 89 (Valentin 2003) . The decay data from Stabin and da Luz (2002) were adopted. Cubic voxels with sizes between 3 and 10 mm (1 mm interval) and source energies in the range 10-2000 keV for electrons and 10-1000 keV for photons were used as input data. The average energy deposition per event (E dep ) is represented as a function of the dimensionless 'normalized radius', de ned as:
where l is the voxel side and R is the distance of the centre of the voxel (i, j, k) from the origin O, where the source voxel is centred. Regarding electrons, for each voxel side l and energy E, E dep (R n ) is tted with the function: Med. Biol. 60 (2015 ) 1945 whereas the tting function for photons is:
a, b, c, r, s and f, g, h are parameters whose values depend on l and E. These parameters were previously reported as tabular data and for generic values of l and E they can be calculated by interpolation (Amato et al 2012) . Then, the VSVs can be calculated as the quotients of energy deposition and voxel mass. For a generic beta-gamma emitting radionuclide, VSVs are obtained by a summation over all monoenergetic photon and electron emissions and an integration over the beta spectrum. A further generalization would allow also to obtain VSVs for different tissues, performing appropriate rescaling of the tting parameters as a function of the tissue density (Amato et al 2013b) . (2) if the voxel ratio is not integer, an additional step of interpolation is carried out.
2.1.4. Local energy deposition. The LED assumption allows calculating the beta contribution to the 3D dose distribution by multiplying the cumulated activity in the voxel for a unique dosimetric factor. The LED approach was initially reported by Bolch et al (1999) and assumes that all kinetic energy released from the beta emissions is locally absorbed within the source voxel (i.e. no charged particle escape). Consequently, for a continuous beta spectrum, the dosimetric factor is calculated as the quotient of the mean beta energy emitted per decay (E β mean ) and the mass of the voxel:
This calculation approach was recently adopted for voxel-based phantoms (Ljungberg and Sjögreen-Gleisner 2011) and clinical 3D dosimetry (Chiesa et al 2012) . Recently, a new method based on LED was proposed, which rescales the dosimetric factor according to the mean absorbed dose to the target, accounting also for photon emissions (Traino et al 2013) .
The original LED calculation approach adopted in this study employs equation (7) to calculate the beta dosimetric factor, while for radionuclides also emitting photons, the result of a convolution calculation with VSVs for the emitted photons was added to the beta absorbed dose evaluated under the LED assumption. The VSVs for photon emissions used here were previously obtained (Pacilio et al 2009 , Lanconelli et al 2012 . , elemental composition as de ned by Cristy and Eckerman (1987) , decay spectra from Stabin and da Luz (2002)). Moreover, the VSVs reported by the MIRD Committee (Bolch et al 1999, available for 90 Y and 131 I) were also used for comparison. Diametral dose pro les and cDVHs were calculated for each case, reporting some examples. The cDVH is the integral of the differential DVH from D to D max (the maximum value of the absorbed dose to the irradiated volume). A systematic analysis of dosimetric differences in terms of D 95% , D 50% (i.e. the minimum value of the absorbed dose to 95% or 50% of the irradiated volume, respectively) and D max was reported.
Clinical cases. Ten patients undergoing a
99m Tc-MAA (macroaggregated albumin) dosimetry study as a surrogate of 90 Y-resin-microspheres radioembolization were analysed to apply the different VSVs in a clinical setting. After the injection of about 74 MBq of 99m Tc-MAA into the hepatic artery, patients underwent a SPECT/CT scan to assess the activity distribution in the liver. All images were acquired with a dual-head gamma camera (In nia II-GE Healthcare, Waukesha, WI) using a LEHR collimator and setting 60 projections, matrix 128 × 128 (4.42 mm voxel size), 30 s per view; double energy window acquisition: 140 keV ± 20% for emissive image and 112 keV ± 5% scatter image window, automatic body contour. To perform attenuation correction, a low dose CT scan was also acquired (120 kV, automatic tube current modulation with Noise Index <25). AW-Server 2.0 (GE Healthcare) was used to coregister rigidly SPECT and CT images, using as landmarks 3 radioactive-opaque markers positioned on the patient skin (one at the sternum level and 2 at hip level) before CT and SPECT acquisitions. Iterative reconstruction of SPECT images was performed using the standard protocol of Xeleris 3.1 workstation (GE Helthcare), with the OSEM algorithm (8 iterations, 6 subsets, no post-reconstruction ltering), including attenuation and scatter corrections. The tomographic spatial resolution was about 13 mm (as results from phantom studies, i.e. with a line source having an inner diameter of 1 mm and about 150 MBq cm −1 of 99m Tc, inserted centrally into the tank of a Carlson Phantom, parallel to its longitudinal axis). Microspheres are not metabolized but remain trapped permanently in the liver so 90 Y physical decay was considered to assess the biokinetics (Chiesa et al 2011 , Walrand et al 2014 . The hypothesis that 99m Tc-MAA describes the 90 Y microsphere distribution was assumed, meaning that in each voxel the activity of 90 Y microspheres is directly proportional to the voxel count in 99m Tc-SPECT. A relative calibration was applied to convert the SPECT images into an activity map, by dividing the total number of counts in the whole liver region by the total injected activity (Dieudonné et al 2011 , Chiesa et al 2012 . For the purpose of this study, we assumed that all patients were injected with 1 GBq of 90 Y and that the target region of each patient was de ned as the iso-count level of 50% of the maximum value. The 3D absorbed dose distributions for the different VSVs tables were calculated by convolving the 3D cumulated activity map with the corresponding VSVs matrix using MATLAB version 7.9.0.529 (R2009b). Again, the results obtained with the VSVs calculated by Lanconelli et al (2012) were used as reference. Comparisons were performed in terms of dose pro les and cDVHs. The differences (mean value and range of variation), in terms of D 95% , D 50% , D max , between the results obtained with each tested method and those derived with the reference VSVs, were reported for all patients.
Results

Direct comparison between VSVs data sets
The comparison between the VSVs data sets for a voxel size of 3 mm is shown in gure 1 for 90 Y and 131 I. The methods described in sections 2.1.1, 2.1.2, 2.1.3 and 2.1.4 are hereinafter denoted as 'Konvox', 'AM', 'Rescaling' and 'LED', respectively. The reference VSVs are denoted as 'Reference data', whereas those from Bolch et al (1999) as 'MIRD' (reported when available). Figure 1 shows the relative percent differences for all VSVs datasets, with respect to the reference data, as a function of the normalized source-target distance (equation (4)).
90 Y VSVs are in good agreement up to about R n = 2. A systematic underestimation (AM) and overestimation (Rescaling) of VSVs can be observed in the 'transition region' (i.e. the region where the energy deposited by bremsstrahlung and/or primary photons begins to prevail on the energy deposited by beta rays, R n range of 2-4). At larger distances (beyond R n = 4.5, where the bremsstrahlung contribution prevails), Rescaling gives accurate results up to R n = 5, whereas AM gives moderate differences (±10%). Konvox remains in agreement with the reference data up to about R n = 3.5, then values reduce rapidly to zero, because the DPKs of Cross et al (1992) do not account for the bremsstrahlung contribution beyond the maximum CSDA range. Differences for MIRD data are notably larger, from about R n = 3. For 131 I, Konvox results are virtually coincident with the reference data; Rescaling gives a good agreement beyond the transition region, whereas at short distances (R n ≤ 1.4), differences are up to about 8%; AM presents appreciable differences, either in the transition region, or beyond (±13%). MIRD data show major deviation in the transition region and large statistical uctuations beyond it. For 90 Y and voxel size of 4.42 mm (of interest for the clinical cases considered here), the trend of VSVs difference is almost the same for all methods (data not reported), except for AM, which shows differences of opposite sign for the rst neighbors, with respect to the 3 mm voxel size. Table 1 reports the percent differences associated with the voxel S factors S 0 0 0 , S 0 0 1 , S 0 1 1 , S 1 1 1 , with respect to the reference data. The rst two columns refer to a voxel size of 3 mm, whereas the differences associated to 90 Y and voxel size of 4.42 mm are reported in the last column.
Analogous Y and the smallest spheroidal cluster (251 voxels) with the unblurred activity distribution are reported in gure 2. For dose pro les, the absorbed dose was normalized with respect to the total cumulated activity in the cluster, assuming physical decay. Y, the diametral absorbed dose pro les ( gure 3(b)) con rm the differences observed by cDVHs data ( gure 3(a)). The mean beta energy considered for LED was derived from the beta spectrum used in the calculations of the reference VSVs, so the absorbed dose to voxel obtained with LED is always equal to or greater than the D max value obtained by convolution of the reference data.
Also for 131 I ( gures 3(c)-(d)), some differences among cDVHs are present and similar to those observed for 90 Y. In this case for the LED method, the absorbed dose contribution obtained by convolution of gamma VSVs was added to that deriving from LED for beta, so cDVHs and dose pro les are no longer represented by a step function and a constant value, respectively. For AM, the differences are consistent with those observed for the corresponding VSVs and within about 5%. The oscillating trend from negative to positive values (from one radionuclide to another) is due to the calculation of VSVs by tting functions, which can yield values sometimes higher, sometimes lower than those obtained for monoenergetic sources, Y and unblurred activity distribution. For dose pro les, the absorbed dose was normalized with respect to total cumulated activity in the cluster, calculated assuming physical decay. from which the tting functions were determined. The highest differences were observed for 90 Y, probably because the methodology is implemented for electrons energy up to 2 MeV, whereas 90 Y beta emissions have energy up to about 2.2 MeV, thus needing an extrapolation above 2 MeV. For Konvox, a negative difference seems systematic for most of the dosimetric indicators. This is consistent with the underestimation of the VSVs for small sourcetarget distances (with respect to the reference dataset), reported in table 1. The differences are limited for all radionuclides, except for 177 Lu (see supplementary data) (stacks.iop.org/ PMB/60/051945), for which slight differences in the beta spectrum energy sampling may play a role. The approach used by Cross et al (1992) to consider the singularity of DPK functions at r = 0 could be also important, mainly for 177 Lu having relatively low beta energies, as pointed by Janicki and Seuntjens (2004) . As regards rescaling, the VSVs calculations are referred to soft tissue with unit density, differently from that used for the reference VSVs (1.04 g cm −3 ). The results in tables 1 and 2 seem coherent with this density difference. Also in this case, slight differences in beta spectrum energy sampling may contribute. For 177 Lu, the differences are higher than other radionuclides (see supplementary data) (stacks.iop.org/PMB/60/051945), probably because 177 Lu has beta emissions with the lowest energy, so the density difference has a higher in uence on the absorbed dose. For LED, the percent differences are obviously related to the amount of lateral electron disequilibrium (i.e.particles escaping from the cluster, not balanced by particles entering from outside). For a given size of the cluster, it is expected that the higher the beta energy, the greater the electron disequilibrium effect, as evidenced by the corresponding increase in ∆D 95% and ∆D 50% . For a given radionuclide, the larger the cluster size, the lower the difference between the cDVH and a step function, so ∆D 95% and ∆D 50% decrease. The differences obtained for 131 I without considering the gamma contribution (i.e. assuming only LED for betas) evidence that the gamma contribution on the absorbed dose increases with mass, while neglecting it differences down to about −10% for D 50% and D max for the largest clusters arise. Figure 4 shows the results for 90 Y and 131 I in the largest spheroidal cluster (4139 voxels) after blurring the activity distribution with a Gaussian PSF having a FWHM of 12 mm. The most evident outcome is the substantial agreement of LED with the other methods.
To study the differences among methods for various degrees of image blurring and cluster sizes, ∆D 95% , ∆D 50% and ∆D max have been calculated for PSFs with FWHM of 6, 8 and 12 mm, for the smallest and the largest clusters. The 3D dose distributions obtained with the reference VSVs for the unblurred activity distribution can be considered as the dosimetric 'gold standard', since the dose calculations obtained by convolution in medium with uniform density must correspond, in principle, to direct MC simulations (Dieudonné et al 2010 , Dieudonné et al 2013 . Figure 5 reports ∆D 95% and ∆D 50% for 90 Y, as a function of the PSF FWHM, for the smallest ( gures 5(a) and (b)) and the largest ( gures 5(c) and
The data denoted as 'MC' correspond to the differences between dosimetric calculations on blurred and unblurred distributions, both performed with the reference VSVs. Figure 6 reports the ∆D 95% and ∆D 50% for 131 I, as a function of the PSF FWHM, for the smallest ( gures 6(a) and (b)) and the largest ( gures 6(c) and (d) 3.2.2. Clinical cases. All patients examined showed very similar trends of dosimetric results, so cDVHs and dose pro les were reported just for one patient, as an example. Figure 7 reports: (a) dose image (transaxial slice) obtained with the reference VSVs and the position for dose pro le sampling, (b) cDVHs for a VOI (volume of interest) de ned by an iso-count level of 50% (with respect to the maximum count value), (c) the dose pro les for several VSVs tables and (d) the percent differences for the dose pro les, with respect to the results obtained with the reference VSVs. The uptaking VOIs resulted in the range 8-56 cm 3 . Reference 3D dose distributions (deriving from unblurred activity distributions) are not available in these cases, so the comparison was performed with respect to the dosimetric results obtained with the reference VSVs on the same images, even though they cannot represent reference dose distributions. Table 3 reports the mean difference and the corresponding variation range, for dosimetric indicators (with respect to the results obtained with the reference VSVs) for all treated patients. Outcomes for the large cluster, with a blurred activity distribution (FWHM = 12 mm), are also reported in the last three columns for comparison. 
Discussion
Direct comparison among VSVs data sets
The most evident differences among the various methods are observed in the transition region, or beyond the maximum continuous-slowing-down-approximation range (where the energy is deposited solely by bremsstrahlung and/or primary gamma rays). Noteworthy, the dosimetric differences in the 3D dose distributions are mainly due to the VSVs referred to self-irradiation (i.e. S 0 0 0 ) and rst neighbors target voxels (Pacilio et al 2009 , Lanconelli et al 2012 .
Dose distributions with voxel-based models
When considering a perfect spatial resolution, the LED assumption with a uniform activity distribution yields a uniform absorbed dose distribution within the target, so the corresponding cDVH is a step function. On the other hand, convolution calculations evidence the effects of lateral electron disequilibrium. This effect is maximized when the smallest cluster and the most energetic beta emitter are considered (see gure 2). The DPKs convolution has proved an excellent trade-off among methods, with a good accuracy which could be further improved provided that updated DPKs are used.
When the image blurring is considered, differences between the cDVHs obtained by the several methods (above all, for LED) tend to decrease. The differences in the high dose region of the cDVHs (see gures 4(a) and (c)), represented by the central voxels of the cluster, remain essentially unchanged, as also evidenced by the dose differences in the central region of dose pro les ( gures 4(b) and (d)). On the contrary, the absorbed dose in voxels near the edges decreases sharply, producing a strong decrease of D 95% and D 50% and masking the differences among the methods.
Generally, image blurring causes a strong decrease of the dosimetric indicators, regardless of the method used, as evidenced in gures 5 and 6 (as well as in gures 2(s) and 3(s) of the supplementary material) (stacks.iop.org/PMB/60/051945). For example, for 90 Y and the smallest cluster (24 mm diameter), D 95% decreases at about −45% with respect to the reference value and as expected, this decrease is less severe when the cluster size increases (about −30% for the largest cluster). Also for LED, D 95% decreases strongly when increasing the blurring effects, until becoming comparable with the other methods. This is because the blurring of the true activity distribution by the PSF spreads the dose out more than convolution with the VSVs kernels. For ∆D 50% and the smallest cluster ( gures 5(b) and 6(b)), the general trend is similar to ∆D 95% , whereas for the largest cluster ( gures 5(c) and 6(c)), ∆D 50% varies less abruptly with increasing FWHM, for all methods and radionuclides (see also gures 2(s) and 3(s) in the supplementary material) (stacks.iop.org/PMB/60/051945). As regards ∆D max (data not reported), the trend generally observed for all radionuclides showed, for the smallest cluster, a decrease with FWHM increasing (starting from a FWHM of 6 mm), whereas for the largest cluster, ∆D max remains constant after Gaussian ltering (whichever FWHM value). In summary, LED yields a 3D dose distribution more and more similar with increasing of the blurring, until it becomes almost equivalent to that obtained with VSVs convolution, at typical spatial resolutions of clinical SPECT images. At the same time, blurring effects reduce slightly also the differences among the methods for VSVs calculations.
The data trend due to partial volume effects presented here is not surprising, however the impact that the limited spatial resolution of the SPECT images has on the dose map calculation is too often disregarded in dosimetric analyses. Actually, the spatial resolution of SPECT images is the main limiting factor for accurate dosimetry in small structures, nevertheless, the recent publications studying extensively these issues are few (Ljungberg and Sjögreen-Gleisner 2011, Pasciak et al 2014) .
In the present work, an extensive analysis of the in uence of SPECT image blurring in dosimetric assessments is also proposed. The severe degradation of cDVHs due to image blurring here observed is in good agreement with the data reported by Ljungberg and Sjögreen-Gleisner (2011) for tumour dosimetry, even though several differences are present between the two studying methodologies. In that previous publication, data are referred to a greater voxel size (6.5 mm) and cDVHs were obtained from MC simulations of experimental images, so involving the reconstruction process. In the present work, a 3 mm voxel size was considered and the tomographic reconstruction was not involved, focusing on voxel-based models. The method of tomographic reconstruction of experimental images could introduce further in uences on the dose maps (e.g. the noise, above all when using a large number of iterations in an iterative MLEM/OSEM algorithm, or ringing artifacts when using the collimator-response correction) which would require additional, dedicated studies (Cheng et al 2013) . The study by Pasciak et al (2014) presented an extensive analysis of the blur impact on dosimetry, but focused just on 90 Y, whereas the data here presented are referred to several radionuclides. For 90 Y, a general agreement can be noted also with that previous work, even though a direct comparison is not easy, due to differences in the dosimetric indicators: integral DVHs (i.e. the integral of the differential DVH from 0 to a given dose value) and related range of error (associated to the entire dose interval) in Pasciak et al (2014) , cDVHs and associated ∆D 95% , ∆D 50% and ∆D max in this work.
Today current interests in TRT are: correlation between tumor response and dosimetric indicators such as EUBED (whose calculation is based on the differential DVH), D 90% or D 70% ; combination of TRT and external radiation therapy, which requires accurate 3D dosimetry to avoid toxicity and increase ef cacy (Hobbs et al 2011 , Ferrari et al 2012 , Fourkal et al 2013 , Grimes et al 2013 , Cremonesi et al 2014 . Blurring effects could severely affect the 
Clinical cases
All cDVHs showed a very similar shape and the differences among them are limited. The comparisons among dose pro les evidenced limited differences, having a nearly constant trend for the AM, Konvox and Rescaling, whereas LED shows an oscillating trend and could reach differences higher than 20-30%. For the AM, limited differences of the dosimetric indicators are always negative, as also con rmed by dose pro les (see gure 7(d)), differently from the largest spheroidal cluster (always positive for 90 Y, see table 3 ). This is due to the peculiarity of the method: for clinical cases, the voxel size (4.42 mm) differs from voxel-based models (3 mm). Since the VSVs are calculated with a new t function, the sign of the dosimetric differences can change. Indeed, most of the differences associated to the VSVs reported in table 1 have an opposite sign for a voxel size of 4.42 mm, with respect to 3 mm. As regards Konvox and Rescaling, the differences of the dosimetric indicators are very similar to those obtained for 90 Y in spheroidal clusters. So, the differences among calculation methods of VSVs are negligible also for clinical cases and the clinical condition of non-uniform activity distributions does not substantially change the differences among methods obtained with a blurred (uniform) activity distribution in a spheroidal cluster (except for the sign change of AM, due to the change in voxel size). As regards LED, differences are still limited, but considerably higher than others and also higher than the corresponding values obtained with voxel-based models, probably due to the in uences of the non-uniformity in the activity distribution. The differences' trend is in substantial agreement with the work of Pasciak et al (2014) , where it was postulated that the blur introduced by the scanner PSF combined with DPK convolution would result in over-estimation of the distribution of beta energy deposition away from the site of decay. Unfortunately, the reference dose distribution is unknown in clinical cases, so it is not possible to assess the most accurate methodology.
Conclusion
All methods here considered for VSVs calculation yield similar dosimetric results on voxelbased models with unblurred activity distributions, with differences limited or easily explainable. On the contrary, LED is not suitable in voxel-based models with unblurred activity distribution, or with imaging systems with high resolving power. The dosimetric differences decrease after blurring the activity distribution with Gaussian lters of increasing width, representing the limited spatial resolution of clinical SPECT images. The method of convolution of DPKs represents an advantageous strategy for calculation of VSVs, ensuring adequate accuracy without need of direct MC simulations. With blurring typically representative of the nite spatial resolution of clinical SPECT systems, LED has proved a useful trade-off, between ease of use and accuracy, to perform 3D dosimetry, even though in clinical cases dose differences with respect to reference data resulted higher than those of other methods. Partial volume effects effectively smooth results and reduce differences between methods, however they introduce errors in all methods compared to the true dose distribution. Partial volume effects of clinical SPECT images resulted the main concern for dosimetric accuracy.
Considering that underestimation up to about 60% for D 95% (or similarly D 90% ) and 50% for D 50% could result for volumes of size about 2-fold the SPECT spatial resolution, the utility of 3D dosimetry could be highly questionable for small tumors, unless an adequate correction strategy for partial volume effects is adopted. Even for relatively 'large' VOIs (5-fold the spatial resolution), partial volume effects could in uence considerably dosimetric indicators associated with high percentages of irradiated volume in cDVHs.
